New hope for bladder cancer patients who failed standard treatment

NCT ID NCT03945162

Recruiting now Disease control Sponsor: Theralase® Technologies Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called Ruvidar, given directly into the bladder, for people with a type of bladder cancer that did not respond to or could not tolerate standard BCG therapy. About 90 adults will receive up to three treatment sessions. The main goal is to see if the drug can make the cancer disappear completely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER ("NMIBC") UNRESPONSIVE/INTOLERANT TO BCG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder carcinoma in situ non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms transitional cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER ("NMIBC") UNRESPONSIVE/INTOLERANT TO BCG

Contacts and locations

Locations

Site 01-001 - University Health Network - Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2C4, Canada
Site 01-002- London Health Sciences Centre - Victoria Hospital
RECRUITING

London, Ontario, N6A 5W9, Canada
Site 01-003 - McGill University Health Centre - Glen-Cedars Cancer Centre
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Site 01-004 - Nova Scotia Health Authority - Centre for Applied Urology Research
RECRUITING

Halifax, Nova Scotia, B3H 2Y9, Canada
Site 01-005 - The Vancouver Prostate Centre - Diamond Health Care Centre - Vancouver General Hospital
RECRUITING

Vancouver, British Columbia, V5Z 1M9, Canada
Site 01-014 - St. Joseph's Healthcare
RECRUITING

Hamilton, Ontario, L8N 4A6, Canada
Site 02-006 - Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Site 02-007 - Urology Associates, P. C
RECRUITING

Nashville, Tennessee, 37209, United States
Site 02-008 - MidLantic Urology
TERMINATED

Bala-Cynwyd, Pennsylvania, 19004, United States
Site 02-009 - Virginia Urology
TERMINATED

Richmond, Virginia, 23235, United States
Site 02-010 - Urology San Antonio P. A
TERMINATED

San Antonio, Texas, 78229, United States
Site 02-011 - University of Wisconsin Health University Hospital
RECRUITING

Madison, Wisconsin, 53792, United States
Site 02-012 - University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
Site 02-015 - Associated Medical Professionals of New York
RECRUITING

Syracuse, New York, 13210, United States
Site 02-016 - Urology of Indiana
RECRUITING

Greenwood, Indiana, 46143, United States
Site 02-017 - Central Ohio Urology Group
RECRUITING

Gahanna, Ohio, 43230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.